ea0098c11 | Clinical – Chemo/SSA/Biologics | NANETS2023
McGlothlin, MD John D.
, Dilmaghani, MD Saam
, Hazim, MD Antonious Z.
, Hobday, MD Timothy J.
, Sonbol, MD Mohamad B.
, Starr, DO Jason S.
, Eiring, PA-C Rachel A.
, Graham MBBS Rondell P.
, Halfdanarson, MD Thorvardur R.
Background: Low- (G1) and intermediate-grade (G2) neuroendocrine tumors (NET) are defined by lower mitotic rates and genetic mutations that rarely cause transformation to high-grade (G3) neoplasm. Yet a proportion of patients with de novo low-grade NETs progress to G3 disease or even neuroendocrine carcinoma (NEC). We aimed to highlight cases of low-grade G1 and G2 NETs that eventually transformed to G3 pathology on repeat biopsy and describe characteristics that portend high-...